Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort

Trial Profile

Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Boceprevir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Results of a pooled analysis of two trials (HEPAVIR and GEHEP-MONO; n=309), assessing influence of HIV on changes in liver function in Cirrhosis, presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 14 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
    • 14 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top